ArticleBulletin of experimental biology and medicine2025
Effects of MicroRNA-19b Carried by Endothelial Microparticles on the Phenotypic Switching of Vascular Smooth Muscle Cells and the Working Mechanism.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study examined implication of miRNA-19b carried by endothelial microparticles (EMPs) in phenotypic switching of vascular smooth muscle cells (VSMCs) and the mechanisms underlying this transformation. The functions of miRNA-19b were assessed by phenotypic switching, proliferation, and migration of VSMCs. The target genes of miR-19b associated with proliferation and migration were revealed by analysis of TargetScan and miRanda databases and verified with luciferase assay. Experiments showed that EMPs could transfer miRNA-19b into VSMCs. Elevated content of miRNA-19b increased expression of contractile phenotypic markers SMA and SM22α and inhibited proliferation and migration of VSMCs. The direct target gene of miRNA-19b turned out to be the mitogen-activated protein kinase 6 (MAPK6). Thus, miRNA-19b in EMPs could inhibit phenotypic transformation of VSMCs from the contractile phenotype to synthetic one and reduce proliferation and migration by down-regulating MAPK6 expression, which can potentially inhibit the development of atherosclerosis.
Indexed as
Identifiers
41186823What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.